PERTUZUMAB OVERCOMES T-DM1 RESISTANCE

Clin Cancer Res. 2013 Nov 15. [Epub ahead of print]

Pertuzumab protects the Achilles' heel of trastuzumab-emtansine.

Gwin WR, Spector NL.

Source

Medicine, Duke University.

Abstract

T-DM1 represents a significant advancement in the treatment of HER2+ breast cancers. Its clinical efficacy however, will be limited by development of therapeutic resistance. In this report, the HER3 ligand neuregulin is shown to mediate T-DM1 resistance, which was overcome by administration of pertuzumab, a steric inhibitor of HER2 dimerization.